nodes	percent_of_prediction	percent_of_DWPC	metapath
Masoprocol—IGF1R—forebrain—attention deficit hyperactivity disorder	0.0497	0.102	CbGeAlD
Masoprocol—IGF1R—cardiovascular system—attention deficit hyperactivity disorder	0.042	0.0861	CbGeAlD
Masoprocol—CYP2J2—forebrain—attention deficit hyperactivity disorder	0.0337	0.069	CbGeAlD
Masoprocol—CYP2J2—cardiovascular system—attention deficit hyperactivity disorder	0.0285	0.0584	CbGeAlD
Masoprocol—IGF1R—nervous system—attention deficit hyperactivity disorder	0.027	0.0553	CbGeAlD
Masoprocol—IGF1R—central nervous system—attention deficit hyperactivity disorder	0.026	0.0532	CbGeAlD
Masoprocol—IGF1R—cerebellum—attention deficit hyperactivity disorder	0.0254	0.052	CbGeAlD
Masoprocol—LTB4R—brain—attention deficit hyperactivity disorder	0.025	0.0512	CbGeAlD
Masoprocol—ALOX5—cardiovascular system—attention deficit hyperactivity disorder	0.0225	0.046	CbGeAlD
Masoprocol—CYP2J2—midbrain—attention deficit hyperactivity disorder	0.0223	0.0456	CbGeAlD
Masoprocol—IGF1R—brain—attention deficit hyperactivity disorder	0.0206	0.0423	CbGeAlD
Masoprocol—LTB4R—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.0197	0.0452	CbGpPWpGaD
Masoprocol—IGF1R—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.0193	0.0443	CbGpPWpGaD
Masoprocol—CYP19A1—forebrain—attention deficit hyperactivity disorder	0.0184	0.0376	CbGeAlD
Masoprocol—CYP2J2—nervous system—attention deficit hyperactivity disorder	0.0183	0.0375	CbGeAlD
Masoprocol—CYP2J2—central nervous system—attention deficit hyperactivity disorder	0.0176	0.0361	CbGeAlD
Masoprocol—CYP2J2—cerebellum—attention deficit hyperactivity disorder	0.0172	0.0353	CbGeAlD
Masoprocol—ALOX5—nervous system—attention deficit hyperactivity disorder	0.0144	0.0295	CbGeAlD
Masoprocol—IGF1R—Posttranslational regulation of adherens junction stability and dissassembly—BDNF—attention deficit hyperactivity disorder	0.0143	0.0329	CbGpPWpGaD
Masoprocol—CYP2J2—brain—attention deficit hyperactivity disorder	0.014	0.0286	CbGeAlD
Masoprocol—ALOX5—central nervous system—attention deficit hyperactivity disorder	0.0139	0.0284	CbGeAlD
Masoprocol—ALOX5—cerebellum—attention deficit hyperactivity disorder	0.0136	0.0278	CbGeAlD
Masoprocol—IGF1R—SHP2 signaling—BDNF—attention deficit hyperactivity disorder	0.0123	0.0283	CbGpPWpGaD
Masoprocol—Dobutamine—COMT—attention deficit hyperactivity disorder	0.0114	0.149	CrCbGaD
Masoprocol—ALOX5—brain—attention deficit hyperactivity disorder	0.011	0.0226	CbGeAlD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.011	0.0252	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0107	0.0247	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0107	0.0245	CbGpPWpGaD
Masoprocol—CYP19A1—nervous system—attention deficit hyperactivity disorder	0.00997	0.0204	CbGeAlD
Masoprocol—CYP19A1—central nervous system—attention deficit hyperactivity disorder	0.0096	0.0197	CbGeAlD
Masoprocol—L-DOPA—DRD5—attention deficit hyperactivity disorder	0.00946	0.124	CrCbGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00938	0.0216	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00919	0.0211	CbGpPWpGaD
Masoprocol—Dopamine—DRD5—attention deficit hyperactivity disorder	0.0088	0.115	CrCbGaD
Masoprocol—LTB4R—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00821	0.0189	CbGpPWpGaD
Masoprocol—CYP19A1—FSH signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00765	0.0176	CbGpPWpGaD
Masoprocol—CYP19A1—brain—attention deficit hyperactivity disorder	0.00762	0.0156	CbGeAlD
Masoprocol—IGF1R—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00753	0.0173	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00744	0.0171	CbGpPWpGaD
Masoprocol—CYP2J2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00739	0.017	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00715	0.0164	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.007	0.0161	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0065	0.0149	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00637	0.0146	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00604	0.0139	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00602	0.0138	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00585	0.0135	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00575	0.0132	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00568	0.0131	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00557	0.0128	CbGpPWpGaD
Masoprocol—Dopamine—COMT—attention deficit hyperactivity disorder	0.00555	0.0725	CrCbGaD
Masoprocol—LTB4R—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00547	0.0126	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00529	0.0122	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00518	0.0119	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00502	0.0115	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00493	0.0113	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00487	0.0112	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00485	0.0112	CbGpPWpGaD
Masoprocol—L-DOPA—DRD4—attention deficit hyperactivity disorder	0.00484	0.0632	CrCbGaD
Masoprocol—LTB4R—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.0048	0.011	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00454	0.0104	CbGpPWpGaD
Masoprocol—Dopamine—DRD4—attention deficit hyperactivity disorder	0.0045	0.0588	CrCbGaD
Masoprocol—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00429	0.00986	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00424	0.00975	CbGpPWpGaD
Masoprocol—Dopamine—MAOA—attention deficit hyperactivity disorder	0.00419	0.0547	CrCbGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—EP300—attention deficit hyperactivity disorder	0.00418	0.0096	CbGpPWpGaD
Masoprocol—L-DOPA—DRD3—attention deficit hyperactivity disorder	0.00417	0.0545	CrCbGaD
Masoprocol—L-DOPA—DRD1—attention deficit hyperactivity disorder	0.0041	0.0535	CrCbGaD
Masoprocol—LTB4R—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00404	0.00928	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00396	0.00909	CbGpPWpGaD
Masoprocol—CYP2J2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00395	0.00909	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00394	0.00906	CbGpPWpGaD
Masoprocol—CYP2J2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00393	0.00902	CbGpPWpGaD
Masoprocol—CYP2J2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.0039	0.00896	CbGpPWpGaD
Masoprocol—Dopamine—DRD3—attention deficit hyperactivity disorder	0.00388	0.0507	CrCbGaD
Masoprocol—LTB4R—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00382	0.00878	CbGpPWpGaD
Masoprocol—Dopamine—DRD1—attention deficit hyperactivity disorder	0.00381	0.0498	CrCbGaD
Masoprocol—LTB4R—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00375	0.00863	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00371	0.00852	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00371	0.00852	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00367	0.00843	CbGpPWpGaD
Masoprocol—Dopamine—SLC6A3—attention deficit hyperactivity disorder	0.00361	0.0472	CrCbGaD
Masoprocol—LTB4R—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00359	0.00826	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00345	0.00794	CbGpPWpGaD
Masoprocol—CYP19A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00339	0.0078	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00323	0.00742	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00318	0.0073	CbGpPWpGaD
Masoprocol—L-DOPA—DRD2—attention deficit hyperactivity disorder	0.00289	0.0377	CrCbGaD
Masoprocol—IGF1R—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00275	0.00631	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00274	0.0063	CbGpPWpGaD
Masoprocol—Dopamine—SLC6A4—attention deficit hyperactivity disorder	0.0027	0.0353	CrCbGaD
Masoprocol—Dopamine—DRD2—attention deficit hyperactivity disorder	0.00268	0.0351	CrCbGaD
Masoprocol—LTB4R—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00252	0.00579	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00249	0.00572	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00242	0.00556	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.0024	0.00551	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00223	0.00512	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00218	0.005	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00217	0.00498	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00216	0.00496	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00214	0.00493	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00212	0.00488	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00212	0.00488	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.0021	0.00481	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00208	0.00478	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00202	0.00465	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00196	0.0045	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00195	0.00449	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00193	0.00443	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.0019	0.00437	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00184	0.00423	CbGpPWpGaD
Masoprocol—CYP19A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00182	0.00417	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.0018	0.00415	CbGpPWpGaD
Masoprocol—CYP19A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.0018	0.00414	CbGpPWpGaD
Masoprocol—CYP19A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00179	0.00411	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00177	0.00407	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00177	0.00407	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00162	0.00372	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00147	0.00338	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00144	0.00331	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00137	0.00314	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00129	0.00296	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00125	0.00287	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00124	0.00285	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.0012	0.00275	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00116	0.00266	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00114	0.00262	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00112	0.00258	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00112	0.00256	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00112	0.00256	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.0011	0.00252	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00109	0.00251	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00105	0.00241	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00102	0.00235	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00102	0.00234	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000995	0.00229	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000995	0.00229	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000985	0.00226	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000979	0.00225	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000968	0.00222	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000956	0.0022	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00091	0.00209	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000892	0.00205	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00089	0.00205	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000864	0.00199	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000849	0.00195	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000795	0.00183	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000757	0.00174	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000742	0.00171	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000733	0.00169	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000676	0.00155	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000671	0.00154	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000651	0.0015	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000624	0.00143	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—COMT—attention deficit hyperactivity disorder	0.000603	0.00139	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000598	0.00138	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00058	0.00133	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000512	0.00118	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000512	0.00118	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000504	0.00116	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000469	0.00108	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00041	0.000941	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00039	0.000896	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000389	0.000893	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.00033	0.000759	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000311	0.000714	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000308	0.000708	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000299	0.000687	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—EP300—attention deficit hyperactivity disorder	0.00029	0.000666	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—EP300—attention deficit hyperactivity disorder	0.000258	0.000594	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000133	0.000306	CbGpPWpGaD
